Health
Sumitomo Pharma America Presents New Investigational Data on Enzomenib and Nuvisertib at the 2025 American Society of Hematology Annual Meeting and Exposition
Sumitomo Pharma America, Inc. (SMPA) today presented new clinical data supporting further development of enzomenib, an investigational, oral selective menin inhibitor being researched for the treatment of relapsed or refractory acute leukemia, and nuvisertib, an oral investigational highly selective small molecule PIM1 kinase inhibitor, being researched for the treatment of relapsed or refractory myelofibrosis (MF), at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.
About this update from Sumitomo Pharma Co.ltd.
[{"type":"list","items":[{"val":[{"type":"text","content":"New investigational data from Phase 1/2 study of enzomenib (DSP-5336) in patients with relapsed/refractory acute myeloid leukemia (AML) show clinical activity in various leukemia subtypes driven by genomic alterations ","length":217,"tagName":"p"}]},{"val":[{"type":"text","content":"Promising preliminary data, particularly in patients without prior venetoclax or menin inhibitor exposure, seen in Phase 1 study of enzomenib in combination with venetoclax and azacitidine in patients with relapsed/refractory AML ","length":239,"tagName":"p"}]},{"val":[{"type":"text","content":"Preliminary data from Phase 1/2 study of nuvisertib (TP-3654) in combination with momelotinib in patients with relapsed/refractory myelofibrosis (MF) with anemia show treatment combination appears to be well tolerated with early clinical activity and improvements in spleen and symptom responses","length":295,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":751,"olType":false},{"type":"text","content":"MARLBOROUGH, Mass., Dec. 8, 2025 /PRNewswire/ -- Sumitomo Pharma America, Inc. (SMPA) today presented new clinical data supporting further development of enzomenib, an investigational, oral selective menin inhibitor being researched for the treatment of relapsed or refractory acute leukemia, and nuvisertib, an oral investigational highly selective small molecule PIM1 kinase inhibitor, being researched for the treatment of relapsed or refractory myelofibrosis (MF), at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.","length":553,"tagName":"p"},{"type":"image","alt":"SMPA Logo (PRNewsfoto/Sumitomo Pharma America)","displaySize":"","headline":null,"caption":"SMPA Logo (PRNewsfoto/Sumitomo Pharma America)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":54,"url":"https://media.zenfs.com/en/prnewswire.com/36c67330cea4d215e392946ca6461778"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/s5pb1ghAEWSETpWimf6IZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTk1O2NmPXdlYnA-/https://media.zenfs.com/en/prnewswire.com/36c67330cea4d215e392946ca6461778","width":400,"height":54}},"href":"https://mma.prnewswire.com/media/2206351/Sumitomo_Pharma_updated_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Updated Data Shared with the Use of E...